Eli Lilly is expecting supply disruptions for its blockbuster weight loss and diabetes products to continue through the end of this year, executives told investors.
READ MOREReal Chemistry plans to harness the “Wild West” of GLP-1 social media and reams of competitive data in the drug category with a new platform called IRIS.
READ MOREThe FDA has OK'd the first-ever human trial of prime editing, Prime Medicine announced Monday, opening the door for testing a new technology that backers hope will widen the array of ...
READ MOREWuXi AppTec said it has “unwavering commitment” to protecting its customer’s intellectual property, in the face of allegations it passed a US client's information to Chinese ...
READ MORE